Endometriosis Market Expected to Reach $3.9 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Endometriosis Market," The endometriosis market was valued at $1.2 billion in 2021, and is estimated to reach $3.9 billion by 2031, growing at a CAGR of 12.6% from 2022 to 2031.

Endometriosis is the abnormal growth of uterine cells (endometrial cells) outside the uterus. Endometriosis is one of the most common chronic diseases to fertile women and in some cases women beyond menopause.  Endometriosis is most commonly found in other organs of the pelvis including ovaries, fallopian tubes, and tissue around the uterus and ovaries. There are four types of endometriosis i.e., superficial peritoneal endometriosis, endometriomas (also called chocolate cyst), deeply infiltrating endometriosis, and abdominal wall endometriosis. Endometrioma is a type of cyst formed when endometrial tissue grows in the ovaries. Endometriosis is characterized by dyspareunia, dysmenorrhea, and abdominal pain. Endometriosis can be treated by using gonadotropin-releasing hormone (GnRH) medicines include goserelin and oral contraceptive pills include norethindrone. 

Growth of the Endometriosis Market Size is majorly driven by rise in number of women that suffering from endometriosis, ongoing R&D activities for advanced endometriosis treatments, high adoption of gonadotropin-releasing hormone agonist, increasing awareness regarding endometriosis and rise in focus on women reproductive health. For instance, according to the article of the National Library of Medicine published in June 2022, endometriosis affects approximately 10% of reproductive-aged women and approximately 17 to 44% of women diagnosed with endometriosis will experience an endometrioma. 

In addition, the rise in initiative taken by government and key players to create awareness regarding endometriosis and organization of awareness programs about this disease drives the growth of Endometriosis Industry. For instance, on 12th March of every year, Austria hosts the full-day free programs, online congress to cater knowledge from experts on endometriosis. Endometriosis awareness takes place across the globe during the month of March with a mission to raise awareness regarding endometriosis disease which affects an estimated 200 million worldwide. The Endometriosis Adenomyosis Society of Bangladesh are observing EndoMarch 2022 and raise awareness through social media, scientific webinars, guidelines to doctors, and awareness stand banners in different medical colleges. On 19th and 20th March 2022, Endometriosis and Reproductive Health Foundation in Bulgaria organized a virtual conference called Myths and truths about the disease. In March of every year, the Indian Council of Medical Research (ICMR), National Institute for Research in Reproductive and Child Health (NIRRCH) together with the Endometriosis Clinical and Genetic Research India (ECGRI) are celebrating endometriosis awareness with a series of activities across multiple provinces in India. Hence, such factors drive the growth of endometriosis market. 

Furthermore, the Endometriosis Market Trends such as increase in funding from government for research on endometriosis, rise in research and development of new medicine for endometriosis, rise in product approval drives the Endometriosis Market Growth. For instance, in March 2020, GlaxoSmithKline, a world leader in pain relief, received approval from the U.S. Food and Drug Administration (FDA) for Advil Dual Action with Acetaminophen as an over the counter (OTC) product for pain relief. The exclusive formula is now the first FDA-approved OTC combination of ibuprofen and acetaminophen in the U.S. Advil Dual Action provides relief for multiple symptoms and is the first formulation that combines ibuprofen and acetaminophen, two powerful ingredients indicated for OTC pain relief that work in different ways. 

On the basis of type, the superficial peritoneal lesion segment generated maximum revenue in 2021 and is expected to witness highest CAGR during the forecast period, owing to increase in prevalence of superficial peritoneal lesion, and development of programs to increase in awareness regarding endometriosis. In addition, an increase in funding from government regarding endometriosis research has propelled the growth of superficial peritoneal lesion segment.  

On the basis of treatment, the gonadotropin-releasing hormone (GnRH) medicines is expected to witness highest CAGR during the forecast period, owing to rise in number of endometriosis cases, shift in focus of key players towards care of female reproductive health, and rise in awareness regarding use of gonadotropin-releasing hormone (GnRH) medicines for the treatment of endometriosis.  

On the basis of distribution channel, the online pharmacy is expected to witness the highest CAGR during the forecast period, owing to more convenience, fewer expenses, easy access to patient reviews, and price comparisons facility.  

Depending on region, North America held the largest Endometriosis Market Share in 2021. Asia-Pacific is expected to witness the highest CAGR during the forecast period, owing to increase in populations, surge in healthcare expenditure, increase in awareness regarding reproductive health, and endometriosis.

KEY FINDINGS OF THE STUDY

• On the basis of type, the superficial peritoneal lesion segment held the largest share in the endometriosis market in 2021.
• On the basis of treatment, the oral contraceptives segment held the largest share in the endometriosis market in 2021.
• On the basis of distribution channel, the hospital pharmacy segment held the largest market share in 2021.
• On the basis of region, North America held the largest market share in 2021.